複製鏈接
請複製以下鏈接發送給好友
https://baike.baidu.hk/item/劉哲/18604023
複製
複製成功

劉哲

（曲阜師範大學教授）

鎖定
劉哲教授，男，1977年出生，山東省“泰山學者海外特聘專家”，曲阜師範大學“抗癌藥物開發及診療應用研究所”所長， [1]  化學學科研究中心副主任，山東師範大學博士生導師，濟南大學客座教授，博士後指導教師，英國皇家化學會會員，國際生物無機化學會會員，中國化學會會員。承擔國家自然科學基金、省泰山學者基金等多項基金。多次受邀為ACS、RSC、Elsevier、Springer等國際出版社旗下的眾多刊物審稿。
2008至2011年獲WPRS獎學金，師從英國皇家科學院院士Peter J. Sadler教授，在英國華威大學獲得化學專業博士學位；2012-2015年分別在英國華威大學和瑞士巴塞爾大學從事研究工作，2015年以“泰山學者海外特聘專家”加盟曲阜師範大學，並任“抗癌藥物開發及診療應用研究所”所長。 [2] 
中文名
劉哲
畢業院校
University of Warwick
主要成就
金屬抗癌藥物研發
職    稱
教授

目錄

  1. 1 科研成果
  2. 2 代表性論文
  3. 3 國際專利
  4. 4 國際會議

劉哲科研成果

主要研究領域為生物無機化學，研究方向包括：金屬配合物藥物化學；新型金屬抗癌藥物的設計、開發及作用機理研究；新型納米材料設計、合成及腫瘤診療一體化研究；金屬配合物在生物催化及催化聚合中的應用等。目前在金屬化合物抗癌和生物催化領域均取得了一系列開拓性研究成果，打破了科學界對銥化合物藥用侷限的傳統觀念。對代表性銥化合物（ZL105）開展的抗癌和生物催化研究，已被美國Science Daily [3]  　和英國BBC [4]  連續報道，在國際上產生重大影響。
代表性論文包括Acc. Chem. Res.（IF = 20.833，他引120餘次）1篇, Angew. Chem. Int. Ed.（IF = 13.734，一篇被評為VIP文章）4篇, J. Med. Chem.（IF = 5.614，他引120餘次）1篇。海外期間作為第一完成人蔘與國際科研項目四項，其中重大項目兩項（European Research Council, Swiss National Science Foundation，科研經費156.5萬歐元和25萬瑞士法郎）。 [2] 
設計開發的金屬銥抗癌化合物具有廣譜、高效、低毒的特點，顯示了不同於臨牀鉑類藥物的新奇抗癌機理，能通過DNA雙重作用機制和氧化應激機制(ROS)等多種作用方式殺死癌細胞，並在正常細胞和癌細胞之間有較高的選擇性。現已設計開發了大批具有超強抗癌活性（比臨牀抗癌藥物順鉑高十倍）和廣譜抗癌效果的銥化合物，對肺癌、乳腺癌、卵巢癌、白血病、黑色素瘤等均有特殊療效，且與臨牀鉑類藥物無交叉耐藥性，獲得了中國和歐洲工業界的廣泛興趣，已申請國際專利1項，極具市場開發潛力。
另外，首次報道了金屬化合物和輔酶NADH之間的氫負離子轉移現象，併成功開發了銥-NADH催化體系，該催化系統在生物條件下已成功應用於氫氣、活性氧產生，以及生物醌催化還原等領域，對於金屬化合物抗癌機理研究、活性氧產生機制及生物催化等領域都具有重大意義，展示了其作為生物催化藥物的光明前景。

劉哲代表性論文

  • Wang, C.; Liu, J.; Tian, Z.; Tian, M.; Tian, L.; Zhao, W.; Liu, Z.* Half-Sandwich Iridium N-Heterocyclic Carbene Anticancer Complexes. Dalton Trans. 2017, DOI: 10.1039/C1037DT00575J. （Impact Factor：4.177）
  • Du, J.; Liu, J.; Gong, P.; Tian, M.; Sun, L.; Ji, S.; Zhang, L.; Liu, Z.* Construction of a novel fluorinated graphene-based magnetic nanocomposite and its application in cancer photo-chemotherapy. Mater. Lett. 2017, 196, 165-167. （Impact Factor：2.437）
  • Liu, Z.; Lebrun, V.; Kitanosono, T.; Mallin, H.; Köhler, V.; Häussinger, D.; Hilvert, D.; Kobayashi, S.; Ward, T. R. Upregulation of an Artificial Zymogen by Proteolysis. Angew. Chem. Int. Ed. 2016, 55, 11587–11590. (Impact Factor：11.709)
  • Liu, Z.; Romero-Canelón, I.; Qamar, B.; Hearn, J. M.; Habtemariam, A.; Barry, N. P. E.; Pizarro, A. M.; Clarkson, G. J.; Sadler, P. J. The Potent Oxidant Anticancer Activity of Organoiridium Catalysts, Angew. Chem. Int. Ed. 2014,53, 3941-3946. (VIP，Impact Factor：13.734，reported by BBC and Science Daily)
  • Liu, Z.; Sadler, P. J. Organoiridium Complexes: Anticancer Agents and Catalysts. Acc. Chem. Res. 2014, 47, 1174-1185. (Impact Factor：20.833)
  • Liu, Z.; Deeth, R. J.; Butler, J. S.; Habtemariam, A.; Newton, M. E.; Sadler, P. J. Reduction of Quinones by NADH Catalyzed by Organoiridium Complexes. Angew. Chem., Int. Ed. 2013, 52, 4194-4197. (Impact Factor：13.734)
  • Betanzos-Lara, S.; Liu, Z. (equal first author); Habtemariam, A.; Pizarro, A. M.; Qamar, B.; Sadler, P. J. Organometallic ruthenium and iridium transfer hydrogenation catalysts using coenzyme NADH as a cofactor. Angew. Chem., Int. Ed.2012,51, 3897-3900. (Impact Factor：13.734)
  • Liu, Z.; Romero-Canelón, I.; Habtemariam, A.; Clarkson, G. J.; Sadler, P. J. Potent Half-Sandwich Iridium(III) Anticancer Complexes Containing C^N-Chelated and Pyridine Ligands. Organometallics 2014, 33, 5324-5333. (Impact Factor：4.145)
  • Liu, Z.; Sadler, P. J. Formation of Glutathione Sulfenate and Sulfinate Complexes by an Organoiridium(III) Anticancer Complex. Inorg. Chem. Front. 2014, 1, 668-672. (Impact Factor：4.532)
  • Liu, Z.; Habtemariam, A.; Pizarro, A. M.; Fletcher, S. A.; Kisova, A.; Vrana, O.; Salassa, L.; Bruijnincx, P. C. A.; Clarkson, G. J.; Brabec, V.; Sadler, P. J. Organometallic half-sandwich iridium anticancer complexes. J. Med. Chem. 2011, 54, 3011-3026. (Impact Factor：5.614)
  • Liu, Z.; Salassa, L.; Habtemariam, A.; Pizarro, A. M.; Clarkson, G. J.; Sadler, P. J. Contrasting reactivity and cancer cell cytotoxicity of isoelectronic organometallic iridium(III) complexes. Inorg. Chem. 2011, 50, 5777-5783. (Impact Factor：4.593)
  • Liu, Z.; Habtemariam, A.; Pizarro, A. M.; Clarkson, G. J.; Sadler, P. J. Organometallic iridium(III) cyclopentadienyl anticancer complexes containing C,N-chelating ligands. Organometallics 2011,30, 4702-4710. (Impact Factor：4.145)
  • Gong, P.; Wang, J.; Hou, K.; Yang, Z.; Wang, Z.; Liu, Z.; Han, X.; Yang, S. Small but strong: The influence of fluorine atoms on formation and performance of graphene quantum dots using a gradient F-sacrifice strategy. Carbon 2017, 112, 63-71.（Impact Factor：6.189）
  • Du, J.; Liu, J.; Gong, P.; Tian, M.; Sun, L.; Ji, S.; Zhang, L.; Liu, Z.* Construction of a novel fluorinated graphene-based magnetic nanocomposite and its application in cancer photo-chemotherapy. Materials Letters. 2017
  • Guo, L.; Jing, X.; Xiong, S.; Liu, W.; Liu, Y.; Liu, Z.; Chen, C. Influences of Alkyl and Aryl Substituents on Iminopyridine Fe(II)- and Co(II)-Catalyzed Isoprene Polymerization. Polymers 2016, 8, 389. (Impact Factor：3.043)
  • Fu, Y.; Sanchez-Cano, C.; Soni, R.; Romero-Canelon, I.; Hearn, J. M.; Liu, Z.; Wills, M.; Sadler, P. J. The contrasting catalytic efficiency and cancer cell antiproliferative activity of stereoselective organoruthenium transfer hydrogenation catalysts. Dalton Trans.2016, 45, 8367-8378. (Impact Factor：4.177)
  • Novohradsky, V.; Zerzankova, L.; Stepankova, J.; Kisova, A.; Kostrhunova, H.; Liu, Z.; Sadler, P. J.; Kasparkova, J.; Brabec, V. A dual-targeting, apoptosis-inducing organometallic half-sandwich iridium anticancer complex. Metallomics 2014, 6, 1491-1501. (Impact Factor：4.099)
  • Novohradsky, V.; Liu, Z.; Vojtiskova, M.; Sadler, P. J.; Brabec, V.; Kasparkova, J. Mechanism of Cellular Accumulation of an Iridium(III) Pentamethylcyclopentadienyl Anticancer Complex Containing a C,N-Chelating Ligand. Metallomics 2014, 6, 682-690. (Impact Factor：4.099)
  • Hearn, J. M.; Romero-Canelón, I.; Qamar, B.; Liu, Z.; Hands-Portman, I.; Sadler, P. J. Organometallic Iridium(III) Anticancer Complexes with New Mechanisms of Action: NCI-60 Screening, Mitochondrial Targeting, and Apoptosis. ACS Chem. Biol. 2013, 8, 1335-1343. (Impact Factor：5.442)
  • Qi, Y; Liu, Z.; Li, H.; Sadler, P. J.; O’Connor, P. B. Mapping the protein-binding sites for novel iridium(III) anticancer complexes using electron capture dissociation. Rapid Commun. Mass Spectrom. 2013, 27, 2028-2032. (Impact Factor：2.509)

劉哲國際專利

Habtemariam, A.; Liu, Z.; Soldevila, J. J.; Pizarro, A. M.; Sadler, P. J. Novel Iridium/Rhodium Anti-
Cancer Compounds, PCT Int. Appl. 88p, US9408853 (B2) 2016-08-09；AU2011257002 (B2)
2015-09-03；CA2797921 (A1) 2011-12-01; CN102905705 (A) 2013-01-30 ; EP2575801 (A1)
2013-04-10; WO 2011/148124 A1 2011-12-01.

劉哲國際會議

  • Taishan Academic International Forum on Bio-Inorganic Chemistry and Nano Materials, Qufu, China, 2016, Organizer.
  • The 8 Asian Biological Inorganic Chemistry Conference, Auckland, New Zealand, 2016, Oral lecture.
  • The 13 China Biological Inorganic Chemistry Conference, Shanghai, China, 2016, Oral lecture.
  • The 30 Chinese Chemical Society Congress, Dalian, China, 2016, Invited lecture.
  • Sadler's Symposium on Metals in Life Processes，Sun Yat-sen University，Guangzhou, China, 2015. Invited lecture.
  • The 17 International Conference on Biological Inorganic Chemistry (ICBIC17)，Beijing, China, 2015. Oral lecture.
  • The 12 International Symposium on Applied Bioinorganic Chemistry，Sun Yat-sen University, Guangzhou, China, 2013. Oral lecture.
  • Gordon Research Conference on Metals in Biology, Ventura, CA, USA, 2013. Poster presentation.
  • COST Chemistry D39 working group meeting: "Analysis of DNA Damage by Metal-Based Compounds", Brno, Czech Republic, 2011. Oral lecture.
  • University of Warwick Chemistry Postgraduate Research Symposium, Coventry, United Kingdom, 2011. Oral lecture.
  • 5 International Symposium on Bioorganometallic Chemistry, Ruhr-University Bochum, Germany, 2010. Poster presentation.
  • University of Warwick Chemistry Postgraduate Research Symposium, Coventry, United Kingdom, 2010. Poster presentation.
參考資料